MktsMarkets

enGene Therapeutics Inc.
NASDAQ: ENGNKey statistics
ENGN News
Stories mentioning ENGN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q2 '26Apr 30 | Q1 '26Jan 31 | Q4 '25Oct 31 | Q3 '25Jul 31 | Q2 '25Apr 30 | Q1 '25Jan 31 | Q4 '24Oct 31 | Q3 '24Jul 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 22,195 | 22,255 | 31,722 | 22,575 | 20,209 | 19,974 | 11,273 | 11,549 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 31,968 | 31,185 | 39,481 | 29,947 | 27,124 | 26,613 | 17,455 | 16,759 |
| Operating Income (Loss) | (31,968) | (31,185) | (39,481) | (29,947) | (27,124) | (26,613) | (17,455) | (16,759) |
| Interest Income | 2,663 | 2,740 | 1,975 | 2,233 | 2,488 | 2,730 | 3,024 | 3,380 |
| Interest Expense | ||||||||
| Other Expense | (177.00) | (87.00) | (121.00) | (280.00) | (205.00) | 37.00 | (93.00) | (47.00) |
| Pretax Income | (30,227) | (29,752) | (38,377) | (28,752) | (25,575) | (24,598) | (15,280) | (14,177) |
| Tax Provision | 0.00 | 0.00 | (497.00) | 239.00 | 240.00 | 18.00 | 19.00 | (29.00) |
| Net Income (Loss) | (30,227) | (29,752) | (37,880) | (28,991) | (25,815) | (24,616) | (15,299) | (14,148) |
| Earnings Per Share (Basic) | (0.43) | 0.44 | (0.74) | 0.57 | (0.51) | 0.48 | (0.40) | 0.32 |
| Earnings Per Share (Diluted) | (0.43) | 0.44 | (0.74) | 0.57 | (0.51) | 0.48 | (0.40) | 0.32 |
| Weighted Average Shares Outstanding (Basic) | 69,725 | 67,263 | 51,119 | 51,098 | 51,019 | 50,977 | 37,782 | 44,169 |
| Weighted Average Shares Outstanding (Diluted) | 69,725 | 67,263 | 51,119 | 51,098 | 51,019 | 50,977 | 37,782 | 44,169 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ENGN
enGene Therapeutics Inc. (NASDAQ: ENGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol ENGN. It last traded at $1.60 (Oct 26, 2026, 1:20 PM ET), up 2.6% on the day. That gives enGene Therapeutics a market capitalisation of $104.5M.
Over the past 52 weeks ENGN has traded between $1.40 and $12.25.
For the quarter ended Apr 30, 2026 it reported a net loss of $30.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Apr 30, 2026 | — | -$30.2M |
| Jan 31, 2026 | — | -$29.8M |
| Oct 31, 2025 | — | -$37.9M |
| Jul 31, 2025 | — | -$29.0M |
From enGene Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…